NNRTIs: future prospects.

Area of Science:

• Infectious Diseases
• Pharmacology
• Virology

Background:

• Efavirenz and nevirapine are frequently prescribed non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV treatment.
• Recent clinical data confirm their efficacy against protease inhibitors in treatment-naive patients.
• Both drugs offer convenient once-daily dosing regimens.

Purpose of the Study:

• To compare the clinical relevance, safety profiles, and pharmacological properties of efavirenz and nevirapine.
• To evaluate differences in genital tract penetration and residual viral load (VL) between efavirenz and nevirapine.

Main Methods:

• Review of recent clinical trial data (e.g., ACTG 5142, ACTG 5202, ARTEN trial).
• Analysis of pharmacokinetic data regarding drug penetration into genital tracts.
• Comparison of residual VL levels using ultrasensitive assays in successfully treated patients.

Main Results:

• Both efavirenz and nevirapine demonstrate effectiveness comparable to protease inhibitors.
• Nevirapine shows significantly higher penetration rates into genital tracts compared to efavirenz in both men and women.
• Patients treated with nevirapine more frequently achieved undetectable viral loads (<1 or 2.5 RNA copies/mL) than those treated with efavirenz.

Conclusions:

• Efavirenz and nevirapine remain important therapeutic options for HIV treatment-naive individuals.
• Nevirapine exhibits a more favorable safety profile concerning genital tract penetration and achieving lower residual viral loads compared to efavirenz.
• Differences in pharmacological properties influence treatment outcomes and drug selection.